OVERCOMING THE INNATE RESISTANCE OF CANCER TO THERAPY

Trento, Italy, June 26, 2018 – Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small

Continue Reading

Krebstherapien maßgeschneidert für jeden Patienten

Mainz, 17. Mai 2018 – Jeder Tumor ist anders. “Krebs entsteht durch individuelle Mutationen”, erklärt Prof. Dr. Ugur Sahin. “Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf

Continue Reading

Biomedical Informatics Symposium

Mainz, June 20, 2018 – Computational Analysis becomes ever more important for the advancement of personalized medicine. Bioinformatics accelerate the patient-centric molecular characterization of diseases and lead to a deeper understanding of the underlying mechanisms thus facilitating the development of novel drugs. Progress in Artificial Intelligence has a strong impact on clinical decision making in

Continue Reading

The Evolution of RNA-based Cancer Vaccines

Ghent, Belgium, May 25, 2018 – VIB conference series hosts the MEDICAL BIOTECHNOLOGY focus meeting May 24-25, 2018, in Ghent Belgium. The conference features talks on new disruptive technologies for early diagnosis and more effective therapeutic intervention in established chronic diseases. Dr. Mustafa Diken will share years of experience in his talk “The evolution of

Continue Reading

CIMT 2018 Annual Meeting

Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects. Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination

Continue Reading

Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines

Mainz, Germany, April 18, 2018 – Ugur Sahin, Scientific Director at TRON, has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT – Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years. The ERC Advanced Grants are awarded to well-established, leading principal investigators to pursue ground-breaking projects. SUMMIT is one

Continue Reading

Authors Comment: HLA and Proteasome Expression Map

Insight into the human HLA expression pattern opens up new ways of improving cancer vaccine development The human leukocyte antigen system (HLA system) is a group of genes that are central to the function of the immune system. These protein complexes can be found either on almost all cells (HLA class I complex) or on

Continue Reading

Ugur Sahin and Özlem Türeci publish a review in Science’s Cancer Immunotherapy special issue

Mainz, March 23, 2018 – TRON is delighted to announce a review authored by Ugur Sahin and Özlem Türeci in the journal Science. “Personalized vaccines for cancer immunotherapy” outlines the genetic basis for why almost every cancer is unique, and how with innovations in mutation mapping, target validation and vaccine production, it is possible to

Continue Reading